Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer

被引：9

作者：

Liu, Yi-Fu ^{[1
]}

Fu, Sheng-Qiang ^{[1
]}

Yan, Yu-Chang ^{[1
]}

Gong, Bin-Bin ^{[1
]}

Xie, Wen-Jie ^{[1
]}

Yang, Xiao-Rong ^{[1
]}

Sun, Ting ^{[1
]}

Ma, Ming ^{[1
]}

机构：

[1] Nanchang Univ, Affiliated Hosp 1, Dept Urol, Nanchang 330000, Jiangxi, Peoples R China

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2021年 / 15卷

关键词：

gonadotropin-releasing hormone; prostate cancer; degarelix; relugolix; ANDROGEN-DEPRIVATION THERAPY; ANTIANDROGEN FLARE PROTECTION; URINARY-TRACT SYMPTOMS; III EXTENSION TRIAL; OF-LIFE IMPROVEMENT; OPEN-LABEL; GNRH ANTAGONIST; PHASE-II; JAPANESE PATIENTS; 1-ARM CROSSOVER;

D O I：

10.2147/DDDT.S291369

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Gonadotropin-releasing hormone (GnRH) receptor agonists are still the most commonly used androgen deprivation treatment (ADT) drugs for prostate cancer in clinical practice. Currently, the GnRH receptor antagonists used for endocrine therapy for prostate cancer primarily include degarelix and relugolix (TAK-385). The former is administered by subcutaneous injection, while the latter is an oral drug. Compared to GnRH agonists, GnRH antagonists reduce serum testosterone levels more rapidly without an initial testosterone surge or subsequent microsurges. This review focuses on the mechanism of action of GnRH antagonists and agonists, the developmental history of GnRH antagonists, and emerging data from clinical studies of the two antagonists used as endocrine therapy for prostate cancer.

引用

页码：639 / 649

页数：11

共 50 条

[11] Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
Choi, Seungtaek
Lee, Andrew K.
DRUG HEALTHCARE AND PATIENT SAFETY, 2011, 3 : 107 - 119
[12] Editorial Comment to Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer
Kawahara, Takashi
INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (10) : 837 - 838
[13] Gonadotropin-releasing hormone receptor expression in the human prostate
Tieva, Å
Stattin, P
Wikström, P
Bergh, A
Damber, JE
PROSTATE, 2001, 47 (04) : 276 - 284
[14] The Skeletal Effects of Gonadotropin-Releasing Hormone Antagonists: A Concise Review
Mohamad, Nur-Vaizura
Ima-Nirwana, Soelaiman
Chin, Kok-Yong
ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2021, 21 (10) : 1713 - 1720
[15] Treatment of Breast Cancer With Gonadotropin-Releasing Hormone Analogs
Huerta-Reyes, Maira
Maya-Nunez, Guadalupe
Allan Perez-Solis, Marco
Lopez-Munoz, Eunice
Guillen, Nancy
Olivo-Marin, Jean-Christophe
Aguilar-Rojas, Arturo
FRONTIERS IN ONCOLOGY, 2019, 9
[16] A gonadotropin-releasing hormone antagonist reduces serum adrenal androgen levels in prostate cancer patients
Miyazawa, Yoshiyuki
Sekine, Yoshitaka
Syuto, Takahiro
Nomura, Masashi
Koike, Hidekazu
Matsui, Hiroshi
Shibata, Yasuhiro
Ito, Kazuto
Suzuki, Kazuhiro
BMC UROLOGY, 2017, 17
[17] Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas
Neblett II, Michael F.
Stewart, Elizabeth A.
OBSTETRICS AND GYNECOLOGY, 2023, 141 (05) : 901 - 910
[18] Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor in sheep spinal cord
Dolan, S
Evans, NP
Richter, TA
Nolan, AM
NEUROSCIENCE LETTERS, 2003, 346 (1-2) : 120 - 122
[19] Negative regulation of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor gene expression by a gonadotropin-releasing hormone agonist in the rat hypothalamus
Han, YG
Kang, SS
Seong, JY
Geum, D
Suh, YH
Kim, K
JOURNAL OF NEUROENDOCRINOLOGY, 1999, 11 (03) : 195 - 201
[20] Eliminating Hormones With Orally Active Gonadotropin-releasing Hormone Antagonists
Kotlyar, Alexander M.
Pal, Lubna
Taylor, Hugh S.
CLINICAL OBSTETRICS AND GYNECOLOGY, 2021, 64 (04) : 837 - 849

← 1 2 3 4 5 →